CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target.
Robillard
N
N
Wuillème
S
S
Lodé
L
L
Magrangeas
F
F
Minvielle
S
S
Avet-Loiseau
H
H
D000617:Aminoglycosides / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000032:analysis / Q000096:biosynthesis*; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis / Q000096:biosynthesis*; D014408:Biomarkers, Tumor / Q000032:analysis; D001854:Bone Marrow Cells; D000079982:Gemtuzumab; D020869:Gene Expression Profiling; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology*; D010950:Plasma Cells; D011379:Prognosis; D063268:Sialic Acid Binding Ig-like Lectin 3
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D014408:Biomarkers, Tumor; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab